Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2012

View Archived Issues

Researchers at IRM patent novel Trk-A inhibitors

New glucagon GLP-1 receptor agonists designed in China

U.S. university presents new antibacterials

Bristol-Myers Squibb develops novel candidate influenza drugs

Novel c-Met inhibitors reported

New orally bioavailable TTK inhibitor described

Scientists in U.S. develop new mouse model to study radiation effects

Tetraphase Pharmaceuticals describes antibacterial activity of novel pentacycline

First-in-human data presented on hypomethylating anticancer agent

Amgen reports discovery of novel class of prostanoid EP2 receptor antagonists

Nuron Biotech obtains worldwide license for candidate AD vaccine

Orphan drug status granted to ReGenX BioSciences program

European Commission approves Humira for new indication

Wilex begins phase Ib/II study of WX-554

Enzo Biochem launches test to assess colorectal cancer risk

MacuCLEAR to advance MC-1101 to phase III development

NeurOp obtains NIH grant for schizophrenia drug research

Novel products for cognitive disorders discovered at Mithridion

SkyePharma signs second development contract with RespiVert

Merck & Co. discovers new potential schizophrenia therapies

NIH to evaluate Isotechnika Pharma portfolio

New Quest Diagnostics molecular test cleared by FDA

IntegraGen launches tool to assess autism in children at high risk

Lilly obtains approval in Canada for testosterone replacement therapy

RiboMed launches new prognostic test for grading gliomas

GE Healthcare reports phase III data on flutemetamol (18F)

Fampyra launched in Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...